MBRX — Moleculin Biotech Income Statement
0.000.00%
Last trade - 00:00HealthcareSpeculativeMicro CapNeutral
- $28.91m
- -$21.48m
- 42
- 49
- 41
- 41
Annual income statement for Moleculin Biotech, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2017 December 31st | 2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 8.5 | 15 | 17.5 | 19.7 | 23 |
| Operating Profit | -8.5 | -15 | -17.5 | -19.7 | -23 |
| Total Net Non Operating Interest Income / Expense | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -9.8 | -11.9 | -13.4 | -17.4 | -15.9 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -9.8 | -11.9 | -13.2 | -17.4 | -15.9 |
| Net Income Before Extraordinary Items | |||||
| Extraordinary Items | |||||
| Net Income | -9.8 | -11.9 | -13.2 | -17.4 | -15.9 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -9.8 | -11.9 | -13.2 | -17.4 | -15.9 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -3.22 | -2.75 | -1.95 | -1.76 | -0.591 |